HIV drug, chemical structure.

Strategic timing of antiretroviral treatment neurology sub-study

The aim of the Strategic Timing of AntiRetroviral Treatment (START) Neurology trial is to investigate whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 on neuropsychological functions. This international project is funded by NAIDS / NIH / NIMH/ ANRS, France / BMBF, Germany (01/01/2008-31/12/2017). The START neurology team is chaired by Assoc Prof Edwina Wright, Dr Lucette Cysique is one of the team’s chief investigators and one of the lead neuropsychologists.